Equillium (EQ) Cantor Global Healthcare Conference 2025 summary

Program overview and strategic direction

• Recently completed a $50 million financing to advance a novel aryl hydrocarbon receptor (AhR) modulator program, EQ504, targeting severe autoimmune and inflammatory diseases, with ulcerative colitis as the lead indication.

• $30 million was received upfront, with an additional $20 million contingent on the initiation of clinical development, expected mid-2026.

• EQ504 was acquired from Decheng Capital and is based on a non-toxic, water-soluble, endogenous AhR ligand scaffold, aiming for targeted delivery to the colon.

• The company is leveraging deep expertise in mucosal immunology and plans to prioritize ulcerative colitis and potentially expand to other indications with tailored formulations.

• Investor engagement and awareness activities, including a KOL event, are planned ahead of clinical trial initiation.

Scientific rationale and clinical validation

• AhR modulators regulate immune and barrier functions in tissues such as the gut and skin, with loss of function leading to diseases like colitis and dermatitis.

• Clinical validation comes from natural products (Indigo naturalis, indirubin, indigo) and approved drugs (e.g., Vtama/tapinarof), which show high remission rates and mucosal healing in ulcerative colitis.

• Abivax's obefazimod, though not originally designed as an AhR modulator, shows hallmark cytokine signatures of AhR activation and strong efficacy in preclinical and clinical studies.

• EQ504 is designed to be more potent, selective, and water-soluble than natural or existing tool compounds, addressing challenges of solubility and selectivity.

• Preclinical studies demonstrate superior potency and selectivity over Indigo naturalis constituents, with strong mucosal healing and cytokine induction in animal models.

Development plans and timelines

• All IND-enabling studies are complete; manufacturing of enteric-coated mini-tablets or microspheres is underway, with about six months needed before clinical start.

• Phase I is expected to begin mid-2026, with data anticipated within six months; plans include a standard SAD/MAD design and potential rapid transition to Phase 1b/2a.

• Phase I will assess safety, tolerability, tissue and blood drug levels, and target engagement via induction of IL-10 and IL-22 in healthy volunteers.

• Initial focus is on ulcerative colitis and pouchitis, with future potential for Crohn’s disease and lung indications via formulation changes.

• The approach aims for GI-targeted delivery, optimizing local tissue exposure while minimizing systemic effects.